Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 463 entries
Sorted by: Best Match Show Resources per page
Topical Steroids and CO2 Laser in the Treatment of Refractory Oral Lichenoid Drug Reaction and Lichenoid Contact Lesion: a Case Report.

Acta stomatologica Croatica

Thongprasom K, Sessririsombat S, Singkharotai K, Vathanasanti A, Subbalek K.
PMID: 27688370
Acta Stomatol Croat. 2014 Sep;48(3):224-9. doi: 10.15644/asc48/3/7.

A 54-year-old female presented with severe pain on the gingiva and buccal mucosa. Oral findings revealed generalized fiery red gingiva, ulcerative with white striae covered by pseudo-membranes on both buccal mucosae. She had hypertension, dyslipidemia, subclinical hypothyroidism and arthritis....

Cite
Thongprasom K, Sessririsombat S, Singkharotai K, et al. Topical Steroids and CO2 Laser in the Treatment of Refractory Oral Lichenoid Drug Reaction and Lichenoid Contact Lesion: a Case Report. Acta Stomatol Croat. 2014;48(3):224-9doi: 10.15644/asc48/3/7.
Thongprasom, K., Sessririsombat, S., Singkharotai, K., Vathanasanti, A., & Subbalek, K. (2014). Topical Steroids and CO2 Laser in the Treatment of Refractory Oral Lichenoid Drug Reaction and Lichenoid Contact Lesion: a Case Report. Acta stomatologica Croatica, 48(3), 224-9. https://doi.org/10.15644/asc48/3/7
Thongprasom, Kobkan, et al. "Topical Steroids and CO2 Laser in the Treatment of Refractory Oral Lichenoid Drug Reaction and Lichenoid Contact Lesion: a Case Report." Acta stomatologica Croatica vol. 48,3 (2014): 224-9. doi: https://doi.org/10.15644/asc48/3/7
Thongprasom K, Sessririsombat S, Singkharotai K, Vathanasanti A, Subbalek K. Topical Steroids and CO2 Laser in the Treatment of Refractory Oral Lichenoid Drug Reaction and Lichenoid Contact Lesion: a Case Report. Acta Stomatol Croat. 2014 Sep;48(3):224-9. doi: 10.15644/asc48/3/7. PMID: 27688370; PMCID: PMC4872827.
Copy Download .nbib Format: NLM
Probable hydrochlorothiazide-induced myopericarditis: first case reported.

Case reports in medicine

Mahfood Haddad T, Nawaz MS, Abuzaid AS, Upadhyay S, Bellamkonda P, Mooss AN.
PMID: 25861276
Case Rep Med. 2015;2015:319086. doi: 10.1155/2015/319086. Epub 2015 Mar 15.

Hydrochlorothiazide has never been reported as a reason for myopericarditis. An African American female, with past history of hypertension, coronary artery disease, and sulfa allergy, presented with indolent onset and retrosternal chest pain which was positional, pleuritic, and unresponsive...

Cite
Mahfood Haddad T, Nawaz MS, Abuzaid AS, et al. Probable hydrochlorothiazide-induced myopericarditis: first case reported. Case Rep Med. 2015;2015:319086doi: 10.1155/2015/319086.
Mahfood Haddad, T., Nawaz, M. S., Abuzaid, A. S., Upadhyay, S., Bellamkonda, P., & Mooss, A. N. (2015). Probable hydrochlorothiazide-induced myopericarditis: first case reported. Case reports in medicine, 2015319086. https://doi.org/10.1155/2015/319086
Mahfood Haddad, Toufik, et al. "Probable hydrochlorothiazide-induced myopericarditis: first case reported." Case reports in medicine vol. 2015 (2015): 319086. doi: https://doi.org/10.1155/2015/319086
Mahfood Haddad T, Nawaz MS, Abuzaid AS, Upadhyay S, Bellamkonda P, Mooss AN. Probable hydrochlorothiazide-induced myopericarditis: first case reported. Case Rep Med. 2015;2015:319086. doi: 10.1155/2015/319086. Epub 2015 Mar 15. PMID: 25861276; PMCID: PMC4377349.
Copy Download .nbib Format: NLM
Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA.

Scientia pharmaceutica

Sharma C, Badyal PN, Rawal RK.
PMID: 26839841
Sci Pharm. 2015 Jun 22;83(4):599-610. doi: 10.3797/scipharm.1505-03. Print 2015.

In this study, new and feasible UV-visible spectrophotometric and multivariate spectrophotometric methods were described for the simultaneous determination of hydrochlorothiazide (HCTZ), hydralazine hydrochloride (H.HCl), and reserpine (RES) in combined pharmaceutical tablets. Methanol was used as a solvent for analysis...

Cite
Sharma C, Badyal PN, Rawal RK. Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA. Sci Pharm. 2015;83(4):599-610doi: 10.3797/scipharm.1505-03.
Sharma, C., Badyal, P. N., & Rawal, R. K. (2015). Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA. Scientia pharmaceutica, 83(4), 599-610. https://doi.org/10.3797/scipharm.1505-03
Sharma, Chetan, et al. "Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA." Scientia pharmaceutica vol. 83,4 (2015): 599-610. doi: https://doi.org/10.3797/scipharm.1505-03
Sharma C, Badyal PN, Rawal RK. Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA. Sci Pharm. 2015 Jun 22;83(4):599-610. doi: 10.3797/scipharm.1505-03. Print 2015. PMID: 26839841; PMCID: PMC4727726.
Copy Download .nbib Format: NLM
Prolonged hypernatremia triggered by hyperglycemic hyperosmolar state with coma: A case report.

World journal of nephrology

Vigil D, Ganta K, Sun Y, Dorin RI, Tzamaloukas AH, Servilla KS.
PMID: 25949947
World J Nephrol. 2015 May 06;4(2):319-23. doi: 10.5527/wjn.v4.i2.319.

A man with past lithium use for more than 15 years, but off lithium for two years and not carrying the diagnosis of diabetes mellitus or nephrogenic diabetes insipidus (NDI), presented with coma and hyperglycemic hyperosmolar state (HHS). Following...

Cite
Vigil D, Ganta K, Sun Y, et al. Prolonged hypernatremia triggered by hyperglycemic hyperosmolar state with coma: A case report. World J Nephrol. 2015;4(2):319-23doi: 10.5527/wjn.v4.i2.319.
Vigil, D., Ganta, K., Sun, Y., Dorin, R. I., Tzamaloukas, A. H., & Servilla, K. S. (2015). Prolonged hypernatremia triggered by hyperglycemic hyperosmolar state with coma: A case report. World journal of nephrology, 4(2), 319-23. https://doi.org/10.5527/wjn.v4.i2.319
Vigil, Darlene, et al. "Prolonged hypernatremia triggered by hyperglycemic hyperosmolar state with coma: A case report." World journal of nephrology vol. 4,2 (2015): 319-23. doi: https://doi.org/10.5527/wjn.v4.i2.319
Vigil D, Ganta K, Sun Y, Dorin RI, Tzamaloukas AH, Servilla KS. Prolonged hypernatremia triggered by hyperglycemic hyperosmolar state with coma: A case report. World J Nephrol. 2015 May 06;4(2):319-23. doi: 10.5527/wjn.v4.i2.319. PMID: 25949947; PMCID: PMC4419143.
Copy Download .nbib Format: NLM
Clinical characteristics, treatment patterns and outcomes of Hispanic hypertensive patients.

Progress in cardiovascular diseases

Campbell PT, Krim SR, Lavie CJ, Ventura HO.
PMID: 25537632
Prog Cardiovasc Dis. 2014 Nov-Dec;57(3):244-52. doi: 10.1016/j.pcad.2014.08.006. Epub 2014 Aug 13.

Hispanics are the largest and fastest-growing minority population in the United States, currently comprising about 16.3% (52 million) of the total population. With an increased prevalence of metabolic risk factors in this population, the rate of uncontrolled hypertension (HTN)...

Cite
Campbell PT, Krim SR, Lavie CJ, et al. Clinical characteristics, treatment patterns and outcomes of Hispanic hypertensive patients. Prog Cardiovasc Dis. 2014;57(3):244-52doi: 10.1016/j.pcad.2014.08.006.
Campbell, P. T., Krim, S. R., Lavie, C. J., & Ventura, H. O. (2014). Clinical characteristics, treatment patterns and outcomes of Hispanic hypertensive patients. Progress in cardiovascular diseases, 57(3), 244-52. https://doi.org/10.1016/j.pcad.2014.08.006
Campbell, Patrick T, et al. "Clinical characteristics, treatment patterns and outcomes of Hispanic hypertensive patients." Progress in cardiovascular diseases vol. 57,3 (2014): 244-52. doi: https://doi.org/10.1016/j.pcad.2014.08.006
Campbell PT, Krim SR, Lavie CJ, Ventura HO. Clinical characteristics, treatment patterns and outcomes of Hispanic hypertensive patients. Prog Cardiovasc Dis. 2014 Nov-Dec;57(3):244-52. doi: 10.1016/j.pcad.2014.08.006. Epub 2014 Aug 13. PMID: 25537632.
Copy Download .nbib Format: NLM
Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice.

Family practice

Celis H, Yodfat Y, Thijs L, Clement D, Cozic J, De Cort P, Forette F, Gregoire M, Heyrman J, Stibbe G, Van den Haute M, Staessen J, Fagard R, behalf of the Syst-Eur Investigators o.
PMID: 8671117
Fam Pract. 1996;13(2):138-43.

Background and objective. This interim report from the Syst-Eur trial investigated the level of blood pressure control achieved during the double-blind period in patients followed in general practices. Methods. In the Syst-Eur trial elderly patients (60 years or older)...

Cite
Celis H, Yodfat Y, Thijs L, et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract. 1996;13(2):138-43
Celis, H., Yodfat, Y., Thijs, L., Clement, D., Cozic, J., De Cort P, Forette, F., Gregoire, M., Heyrman, J., Stibbe, G., Van den Haute M, Staessen, J., Fagard, R., & behalf of the Syst-Eur Investigators o. (1996). Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Family practice, 13(2), 138-43.
Celis, et al. "Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice." Family practice vol. 13,2 (1996): 138-43.
Celis H, Yodfat Y, Thijs L, Clement D, Cozic J, De Cort P, Forette F, Gregoire M, Heyrman J, Stibbe G, Van den Haute M, Staessen J, Fagard R, behalf of the Syst-Eur Investigators o. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract. 1996;13(2):138-43. PMID: 8671117.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 11980386
Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):37-55.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses, which has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(1):37-55
Bayes, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(1), 37-55.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,1 (2002): 37-55.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):37-55. PMID: 11980386.
Copy Download .nbib Format: NLM
How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2).

Current controlled trials in cardiovascular medicine

Thijs L, Staessen JA, Beleva S, Birkenhäger WH, Bulpitt CJ, Celis H, Fletcher AE, Kermova R, Leonetti G, Laks T, Mantov S, Nachev C, Sarti C, Tuomilehto J, Fagard RH.
PMID: 11806817
Curr Control Trials Cardiovasc Med. 2001 Oct 18;2(6):298-306. doi: 10.1186/cvm-2-6-298.

BACKGROUND: The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascular complications in elderly patients with isolated systolic hypertension. In an attempt to...

Cite
Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med. 2001;2(6):298-306doi: 10.1186/cvm-2-6-298.
Thijs, L., Staessen, J. A., Beleva, S., Birkenhäger, W. H., Bulpitt, C. J., Celis, H., Fletcher, A. E., Kermova, R., Leonetti, G., Laks, T., Mantov, S., Nachev, C., Sarti, C., Tuomilehto, J., Fagard, R. H. (2001). How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Current controlled trials in cardiovascular medicine, 2(6), 298-306. https://doi.org/10.1186/cvm-2-6-298
Thijs, Lutgarde, et al. "How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2)." Current controlled trials in cardiovascular medicine vol. 2,6 (2001): 298-306. doi: https://doi.org/10.1186/cvm-2-6-298
Thijs L, Staessen JA, Beleva S, Birkenhäger WH, Bulpitt CJ, Celis H, Fletcher AE, Kermova R, Leonetti G, Laks T, Mantov S, Nachev C, Sarti C, Tuomilehto J, Fagard RH. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med. 2001 Oct 18;2(6):298-306. doi: 10.1186/cvm-2-6-298. PMID: 11806817; PMCID: PMC64833.
Copy Download .nbib Format: NLM
Hydrochlorothiazide Increases Efferent Glomerular Arteriolar Resistance in Spontaneously Hypertensive Rats.

Journal of cardiovascular pharmacology and therapeutics

Komatsu K, Numabe A, Ono Y, Frohlich ED.
PMID: 10684400
J Cardiovasc Pharmacol Ther. 1996 Jan;1(1):57-64. doi: 10.1177/107424849600100109.

BACKGROUND: Micropuncture studies were performed to determine the intrarenal hemodynamic effects of two conventional antihypertensive agents, hydrochlorothiazide (HCTZ) and hydralazine (HYDR) alone and in combination. METHODS AND RESULTS: Male spontaneously hypertensive and normotensive Wistar Kyoto rats (19 weeks old)...

Cite
Komatsu K, Numabe A, Ono Y, et al. Hydrochlorothiazide Increases Efferent Glomerular Arteriolar Resistance in Spontaneously Hypertensive Rats. J Cardiovasc Pharmacol Ther. 1996;1(1):57-64doi: 10.1177/107424849600100109.
Komatsu, K., Numabe, A., Ono, Y., & Frohlich, E. D. (1996). Hydrochlorothiazide Increases Efferent Glomerular Arteriolar Resistance in Spontaneously Hypertensive Rats. Journal of cardiovascular pharmacology and therapeutics, 1(1), 57-64. https://doi.org/10.1177/107424849600100109
Komatsu, et al. "Hydrochlorothiazide Increases Efferent Glomerular Arteriolar Resistance in Spontaneously Hypertensive Rats." Journal of cardiovascular pharmacology and therapeutics vol. 1,1 (1996): 57-64. doi: https://doi.org/10.1177/107424849600100109
Komatsu K, Numabe A, Ono Y, Frohlich ED. Hydrochlorothiazide Increases Efferent Glomerular Arteriolar Resistance in Spontaneously Hypertensive Rats. J Cardiovasc Pharmacol Ther. 1996 Jan;1(1):57-64. doi: 10.1177/107424849600100109. PMID: 10684400.
Copy Download .nbib Format: NLM
The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic.

American journal of therapeutics

Drayer JI, Stimpel M, Fox A, Weber M.
PMID: 11854821
Am J Ther. 1995 Aug;2(8):525-531. doi: 10.1097/00045391-199508000-00002.

The antihypertensive characteristics of the angiotensin-converting enzyme inhibitor moexipril were evaluated in 413 patients with baseline setting diastolic blood pressures between 95 and 114 mm Hg. The study was double blind, with patients randomized to placebo or to differing...

Cite
Drayer JI, Stimpel M, Fox A, et al. The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic. Am J Ther. 1995;2(8):525-531doi: 10.1097/00045391-199508000-00002.
Drayer, J. I., Stimpel, M., Fox, A., & Weber, M. (1995). The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic. American journal of therapeutics, 2(8), 525-531. https://doi.org/10.1097/00045391-199508000-00002
Drayer, Jan I.M., et al. "The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic." American journal of therapeutics vol. 2,8 (1995): 525-531. doi: https://doi.org/10.1097/00045391-199508000-00002
Drayer JI, Stimpel M, Fox A, Weber M. The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic. Am J Ther. 1995 Aug;2(8):525-531. doi: 10.1097/00045391-199508000-00002. PMID: 11854821.
Copy Download .nbib Format: NLM
Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.

Clinical drug investigation

Seedat YK, Randeree IG.
PMID: 18370544
Clin Drug Investig. 1998;16(3):229-40. doi: 10.2165/00044011-199816030-00007.

OBJECTIVE: This study compared the antihypertensive effect and acceptability of a perindopril-based group with that of an atenolol-based group in Indian hypertensive type 2 (non-insulin-dependent) diabetic patients.DESIGN AND SETTING: 100 ambulant patients aged between 35 and 69 years were...

Cite
Seedat YK, Randeree IG. Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clin Drug Investig. 1998;16(3):229-40doi: 10.2165/00044011-199816030-00007.
Seedat, Y. K., & Randeree, I. G. (1998). Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clinical drug investigation, 16(3), 229-40. https://doi.org/10.2165/00044011-199816030-00007
Seedat, Y K, and Randeree, I G. "Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol." Clinical drug investigation vol. 16,3 (1998): 229-40. doi: https://doi.org/10.2165/00044011-199816030-00007
Seedat YK, Randeree IG. Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clin Drug Investig. 1998;16(3):229-40. doi: 10.2165/00044011-199816030-00007. PMID: 18370544.
Copy Download .nbib Format: NLM
A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension.

Clinical drug investigation

Saini R, Romanini M, Veglio F.
PMID: 18370462
Clin Drug Investig. 1998;15(1):21-8. doi: 10.2165/00044011-199815010-00003.

A multicentre, randomised, double-blind, parallel-group study of the tolerability and antihypertensive efficacy of once-daily fosinopril 20 mg/hydrochlorothiazide 12.5mg (FOS/HCTZ) compared with once-daily hydrochlorothiazide 25mg (HCTZ) was conducted in 142 patients with non-insulin-dependent diabetes mellitus (NIDDM) and mild to moderate...

Cite
Saini R, Romanini M, Veglio F. A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension. Clin Drug Investig. 1998;15(1):21-8doi: 10.2165/00044011-199815010-00003.
Saini, R., Romanini, M., & Veglio, F. (1998). A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension. Clinical drug investigation, 15(1), 21-8. https://doi.org/10.2165/00044011-199815010-00003
Saini, R, et al. "A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension." Clinical drug investigation vol. 15,1 (1998): 21-8. doi: https://doi.org/10.2165/00044011-199815010-00003
Saini R, Romanini M, Veglio F. A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension. Clin Drug Investig. 1998;15(1):21-8. doi: 10.2165/00044011-199815010-00003. PMID: 18370462.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 463 entries